Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$89.20+7.48%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
6.48 → 6.34 EPS · FY ending Dec 31, 2027 · 10 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 10 to 10; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ZTS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain disciplined cost management to protect profits | A primary condition in Zoetis's published investment case. The stated target is stabilize or improve operating income near $758 million quarterly. | Broken | operating income declines below $700 million quarterly | Operating income: $937M FY2026-Q2; GAAP. Published target: stabilize or improve operating income near $758 million quarterly. Target period is not explicitly aligned with this observation. Aug 6, 2026937,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ZTS is a growth-oriented animal health business whose multi-year view depends on new products and international expansion. The thesis is intact, and recent financial performance is strong, but execution quality is neutral and the evidence snapshot notes a pattern of recent quarterly misses.
The valuation signal is mixed: ZTS is described as cheap versus peers, while the priced-in tag says expectations are stretched. The valuation measure has fallen recently, and the estimated expectations gap is modest, so the snapshot does not point to a simple case of low expectations.
Near term, recent performance is strong, and management is on track with product approvals and international growth; cost control is mixed as spending on research and development has increased modestly. A guidance cut is a key risk, and the snapshot also flags a weakening jobs trend as a possible source of pressure on healthcare names.
Over the next year, the thesis hinges on continued product launches, approvals, and international revenue growth, alongside disciplined costs. A guidance cut or further employment weakening would challenge the setup, while continued earnings strength and higher guidance from healthcare peers would support sector momentum.
For the 1 to 3 year view, the business case remains intact, but elevated risk and stretched expectations make execution and guidance important swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 of 8 supplied quarters. Management reported: “We are taking decisive action to sharpen commercial execution, unlock revenue and continue to drive disciplined cost management.” “FINANCIAL GUIDANCE Zoetis is updating its full year 2025 guidance based on the broader macro trends and operational environment in the back half of the year, and the company's continued disciplined approach to cost management and investment.” Net income was $691.000 million in 2026-Q2.
Delivery assessment Nov 4, 2026Achieve EPS near guidance | A primary condition in Zoetis's published investment case. The stated target is EPS >= $6.85. | Under Pressure | EPS falls below $6.5 | Diluted EPS: $1.65 per share FY2026-Q2; GAAP. Published target: EPS >= $6.85. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20261.65 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow international segment revenue strongly | A supporting condition in Zoetis's published investment case. The stated target is >= 17% YoY growth in international revenue. | Intact | international revenue growth falls below 10% YoY | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue growth near guidance level | A primary condition in Zoetis's published investment case. The stated target is >= $9.82 billion annual revenue. | Broken | annual revenue falls below $9.4 billion | Revenue: $2.468B FY2026-Q2; GAAP. Published target: >= $9.82 billion annual revenue. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20262,468,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$7.37 → $6.34 · observed estimates
$10.12B → $9.34B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $7.37 | $10,119,774,416 | 12 / 14 |
| 2026-07-25 | $7.39 | $10,149,485,380 | 19 / 18 |
| 2026-07-26 | $7.39 | $10,149,485,380 | 19 / 18 |
| 2026-07-27 | $7.37 | $10,118,159,376 | 12 / 14 |
| 2026-07-28 | $7.37 | $10,115,974,223 | 12 / 14 |
| 2026-07-29 | $7.39 | $10,147,664,420 | 19 / 18 |
| 2026-07-30 | $7.39 | $10,147,664,420 | 19 / 18 |
| 2026-07-31 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-01 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-02 | $7.39 | $10,147,664,420 | 19 / 18 |
| 2026-08-03 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-04 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-05 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-06 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-08 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-09 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-10 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-12 | $6.73 | $9,557,042,100 | 18 / 17 |
| 2026-08-13 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-14 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-15 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-16 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-17 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-18 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-19 | $7.35 | $10,088,422,505 | 12 / 14 |
| 2026-08-20 | $6.52 | $9,478,122,794 | 12 / 13 |
| 2026-08-21 | $6.52 | $9,478,122,794 | 12 / 13 |
| 2026-08-22 | $6.52 | $9,478,122,794 | 12 / 13 |
| 2026-08-23 | $6.52 | $9,478,122,794 | 12 / 13 |
| 2026-08-24 | $6.52 | $9,478,122,794 | 12 / 13 |
| 2026-08-25 | $6.46 | $9,429,194,222 | 12 / 13 |
| 2026-08-26 | $6.46 | $9,429,194,222 | 12 / 13 |
| 2026-08-27 | $6.46 | $9,429,194,222 | 12 / 13 |
| 2026-08-28 | $6.46 | $9,429,194,222 | 12 / 13 |
| 2026-08-29 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-08-30 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-08-31 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-01 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-02 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-03 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-04 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-05 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-06 | $6.46 | $9,429,194,222 | 10 / 13 |
| 2026-09-07 | $6.46 | $9,429,194,222 | 10 / 13 |
| 2026-09-08 | $6.46 | $9,429,194,222 | 10 / 13 |
| 2026-09-09 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-10 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-11 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-12 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-13 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-14 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-15 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-16 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-17 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-18 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-19 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-20 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-21 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-22 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-23 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-24 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-25 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-26 | $6.46 | $9,429,194,222 | 11 / 13 |
| 2026-09-27 | $6.46 | $9,429,194,222 | 10 / 12 |
| 2026-09-28 | $6.46 | $9,429,194,222 | 10 / 12 |
| 2026-09-29 | $6.47 | $9,436,393,967 | 10 / 12 |
| 2026-09-30 | $6.47 | $9,436,393,967 | 10 / 12 |
| 2026-10-01 | $6.47 | $9,446,324,736 | 10 / 12 |
| 2026-10-02 | $6.47 | $9,446,324,736 | 10 / 12 |
| 2026-10-03 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-04 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-05 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-06 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-07 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-08 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-09 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-10 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-11 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-12 | $6.48 | $9,455,901,659 | 10 / 12 |
| 2026-10-13 | $6.48 | $9,455,897,944 | 10 / 12 |
| 2026-10-14 | $6.41 | $9,396,595,785 | 11 / 12 |
| 2026-10-15 | $6.41 | $9,396,595,785 | 11 / 12 |
| 2026-10-16 | $6.41 | $9,396,562,452 | 11 / 12 |
| 2026-10-17 | $6.41 | $9,396,562,452 | 11 / 12 |
| 2026-10-18 | $6.41 | $9,401,468,698 | 10 / 12 |
| 2026-10-19 | $6.41 | $9,401,468,698 | 10 / 12 |
| 2026-10-20 | $6.41 | $9,401,468,698 | 10 / 12 |
| 2026-10-21 | $6.38 | $9,382,360,364 | 10 / 12 |
| 2026-10-22 | $6.38 | $9,382,360,364 | 10 / 12 |
| 2026-10-23 | $6.38 | $9,382,360,364 | 10 / 12 |
| 2026-10-24 | $6.38 | $9,381,027,031 | 10 / 12 |
| 2026-10-25 | $6.38 | $9,381,027,031 | 10 / 12 |
| 2026-10-26 | $6.38 | $9,381,027,031 | 10 / 12 |
| 2026-10-27 | $6.38 | $9,381,027,031 | 10 / 12 |
| 2026-10-28 | $6.37 | $9,382,705,389 | 10 / 12 |
| 2026-10-29 | $6.34 | $9,342,915,043 | 10 / 12 |
| 2026-10-30 | $6.34 | $9,342,915,043 | 10 / 12 |
| 2026-10-31 | $6.34 | $9,340,081,710 | 10 / 12 |
| 2026-11-01 | $6.34 | $9,340,081,710 | 10 / 12 |
| 2026-11-02 | $6.34 | $9,340,081,710 | 10 / 12 |
| 2026-11-03 | $6.34 | $9,340,081,710 | 10 / 12 |
| 2026-11-04 | $6.34 | $9,340,081,710 | 10 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 11 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.